Literature DB >> 19850732

Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration.

John E Cho1, Mario Fournier, Xiaoyu Da, Michael I Lewis.   

Abstract

Increased expression of forkhead box O (Foxo) transcription factors were reported in cultured myotubes and mouse limb muscle with corticosteroid (CS) treatment. We previously reported that administration of CS to rats resulted in muscle fiber atrophy only by day 7. The aim of this study, therefore, was to evaluate the time-course changes in the expression of Foxo transcription factors and muscle-specific ubiquitin E3 ligases in rat limb muscle following CS administration. Triamcinolone (TRI; 1 mg x kg(-1) x day(-1) im) was administered for 1, 3, or 7 days. Control (CTL) rats were given saline. Muscle mRNA was analyzed by real-time RT-PCR. Compared with CTL, body weights of TRI-treated animals decreased by 3, 12, and 21% at days 1, 3, and 7, respectively. Muscle IGF-1 mRNA levels decreased by 33, 65, and 58% at days 1, 3, and 7 in TRI-treated rats compared with CTL. Levels of phosphorylated Akt were 28, 50, and 36% lower in TRI animals at these time points. Foxo1 mRNA increased progressively by 1.2-, 1.4-, and 2.5-fold at days 1, 3, and 7 in TRI animals. Similar changes were noted in the expression of Foxo3a mRNA (1.3-, 1.4-, and 2.6-fold increments). By contrast, Foxo4 mRNA was not significantly changed in TRI animals. With TRI, muscle atrophy F box/Atrogin-1 increased by 1.8-, 4.1-, and 7.5-fold at days 1, 3, and 7 compared with CTL rats. By contrast, muscle RING finger 1 increased only from day 7 (2.7-fold). Gradual reduction in IGF-I expression with TRI over the time series paralleled that of Akt. These findings are consistent with a progressive stimulus to muscle protein degradation and the need to process/remove disassembled muscle proteins via the ubiquitin-proteasome system. Elucidating the dynamic catabolic responses to CS challenge is important in understanding the mechanisms underlying muscle atrophy and therapeutic measures to offset this.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850732      PMCID: PMC2885068          DOI: 10.1152/japplphysiol.00704.2009

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  68 in total

1.  Balancing muscle hypertrophy and atrophy.

Authors:  Eric P Hoffman; Gustavo A Nader
Journal:  Nat Med       Date:  2004-06       Impact factor: 53.440

2.  Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters.

Authors:  Mario Fournier; Zhi-Shen Huang; Hongyan Li; Xiaoyu Da; Bojan Cercek; Michael I Lewis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-04-10       Impact factor: 3.619

3.  Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle of rats made catabolic with dexamethasone.

Authors:  D Chrysis; L E Underwood
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

5.  Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.

Authors:  Esther Latres; Ami R Amini; Ashley A Amini; Jennifer Griffiths; Francis J Martin; Yi Wei; Hsin Chieh Lin; George D Yancopoulos; David J Glass
Journal:  J Biol Chem       Date:  2004-11-17       Impact factor: 5.157

6.  Peripheral muscle weakness in patients with chronic obstructive pulmonary disease.

Authors:  S Bernard; P LeBlanc; F Whittom; G Carrier; J Jobin; R Belleau; F Maltais
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

7.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.

Authors:  Jennifer M Sacheck; Akira Ohtsuka; S Christine McLary; Alfred L Goldberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-04-20       Impact factor: 4.310

8.  A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle.

Authors:  F J Kelly; J A McGrath; D F Goldspink; M J Cullen
Journal:  Muscle Nerve       Date:  1986-01       Impact factor: 3.217

9.  The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.

Authors:  David S Waddell; Leslie M Baehr; Jens van den Brandt; Steven A Johnsen; Holger M Reichardt; J David Furlow; Sue C Bodine
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-08       Impact factor: 4.310

10.  Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma.

Authors:  M Decramer; K J Stas
Journal:  Am Rev Respir Dis       Date:  1992-09
View more
  14 in total

1.  Aging and the Mammalian regulatory triumvirate.

Authors:  C David Rollo
Journal:  Aging Dis       Date:  2010-09-10       Impact factor: 6.745

Review 2.  Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases.

Authors:  Rowan S Hardy; Karim Raza; Mark S Cooper
Journal:  Nat Rev Rheumatol       Date:  2020-02-07       Impact factor: 20.543

Review 3.  Muscle atrophy in patients with Type 2 Diabetes Mellitus: roles of inflammatory pathways, physical activity and exercise.

Authors:  Ben D Perry; Marissa K Caldow; Tara C Brennan-Speranza; Melissa Sbaraglia; George Jerums; Andrew Garnham; Chiew Wong; Pazit Levinger; Muhammad Asrar Ul Haq; David L Hare; S Russ Price; Itamar Levinger
Journal:  Exerc Immunol Rev       Date:  2016       Impact factor: 6.308

4.  Intracellular signaling pathways regulating net protein balance following diaphragm muscle denervation.

Authors:  Heather M Argadine; Carlos B Mantilla; Wen-Zhi Zhan; Gary C Sieck
Journal:  Am J Physiol Cell Physiol       Date:  2010-11-17       Impact factor: 4.249

5.  A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure.

Authors:  Monica L Watson; Leslie M Baehr; Holger M Reichardt; Jan P Tuckermann; Sue C Bodine; J David Furlow
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

Review 6.  Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.

Authors:  Sue C Bodine; Leslie M Baehr
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-05       Impact factor: 4.310

7.  Activated protein synthesis and suppressed protein breakdown signaling in skeletal muscle of critically ill patients.

Authors:  Jakob G Jespersen; Anders Nedergaard; Søren Reitelseder; Ulla R Mikkelsen; Kasper J Dideriksen; Jakob Agergaard; Frederik Kreiner; Frank C Pott; Peter Schjerling; Michael Kjaer
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

8.  Genome-wide association study identified a narrow chromosome 1 region associated with chicken growth traits.

Authors:  Liang Xie; Chenglong Luo; Chengguang Zhang; Rong Zhang; Jun Tang; Qinghua Nie; Li Ma; Xiaoxiang Hu; Ning Li; Yang Da; Xiquan Zhang
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

9.  mRNA-seq reveals skeletal muscle atrophy in response to handling stress in a marine teleost, the red cusk-eel (Genypterus chilensis).

Authors:  Jorge E Aedo; Jonathan Maldonado; Víctor Aballai; Juan M Estrada; Macarena Bastias-Molina; Claudio Meneses; Cristian Gallardo-Escarate; Herman Silva; Alfredo Molina; Juan A Valdés
Journal:  BMC Genomics       Date:  2015-12-01       Impact factor: 3.969

10.  PGC1-α over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice.

Authors:  Jessica Cannavino; Lorenza Brocca; Marco Sandri; Roberto Bottinelli; Maria Antonietta Pellegrino
Journal:  J Physiol       Date:  2014-08-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.